Not Yet RecruitingNot Applicable

The Effectiveness of Steroid Nasal Drops in the Olfactory Cleft Combined With Olfactory Training for Patients With PIOD

China100 participantsStarted 2026-03-01

Plain-language summary

This study aims to evaluate the effectiveness of hormone nasal drops in the olfactory cleft combined with olfactory training for treating postinfectious olfactory dysfunction (PIOD). The main questions this clinical trial seeks to answer are: Can the combination of hormone nasal drops and olfactory training improve smell function better than olfactory training alone in PIOD patients? How does this combined treatment work?

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Prospective enrollment of otolaryngology clinic patients aged 18-65 years with olfactory dysfunction. Diagnosis of post-infectious olfactory dysfunction (PIOD) will be based on the PPOD 2023 criteria. Participants must demonstrate olfactory impairment via Sniffin' Sticks testing, with TDI scores (sum of Threshold, Discrimination, and Identification) meeting: (1) Hyposmia: 16 \< TDI \< 30.75; (2) Anosmia: TDI ≤ 15.
✓. Willingness to participate and signed informed consent.

Exclusion criteria

✕. Use of systemic corticosteroids within 4 weeks or intranasal steroids within 2 weeks prior to enrollment.
✕. Severe nasal septum deviation, nasal tumors, acute upper respiratory infections, or uncontrolled allergic rhinitis.
✕. History of functional endoscopic sinus surgery or other nasal procedures within 12 months.
✕. Severe cardiovascular disease, hepatic/renal insufficiency, uncontrolled diabetes, or immune system disorders.
✕. Current or planned pregnancy.
✕. Investigator-determined inability to comply with study requirements (e.g., memory/behavioral disorders, depression, heavy alcohol use, prior non-compliance).

What they're measuring

The Sniffin' Sticks test

Timeframe: Baseline, 1 week, 4 weeks, 8 weeks, and 12 weeks after the initiation of treatment.

Trial details

NCT IDNCT07386860

SponsorPeking University Third Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-12-31

Contact for this trial

Dawei Wu, MD, PhD

13522503401 davidwuorl@163.com

View on ClinicalTrials.gov More Smell Dysfunction trials